Drug intelligence / Profile preview

Proxeed Women

Development stage: Unknown
Lead developer: Alfasigma
Modality: Small Molecules
Administration: Oral

Overview

Proxeed Women is a multi-ingredient dietary supplement developed by Alfasigma (formerly Alfa Wassermann) specifically formulated to support female reproductive health and fertility. The product contains a proprietary blend of metabolic precursors, vitamins, and minerals, including L-carnitine, acetyl-L-carnitine, L-arginine, N-acetyl cysteine, folic acid, and various antioxidants. It is designed to optimize egg quality, support normal hormonal balance, and protect reproductive cells from oxidative damage. Proxeed Women is typically recommended for women who are preparing for pregnancy or undergoing assisted reproductive technologies (ART) to improve the physiological environment for conception.

Brand names: Proxeed Women
Other names: Proxeed Plus Women

Beyond the preview

Go deeper on Proxeed Women.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Proxeed Women.

Explore the full profile